Medullary Thyroid Carcinoma
Biology, management, and treatment of sporadic and hereditary MTC
2025
|
2. Second Edition 2025
Springer International Publishing (Verlag)
978-3-031-80395-6 (ISBN)
Springer International Publishing (Verlag)
978-3-031-80395-6 (ISBN)
- Noch nicht erschienen - erscheint am 13.05.2025
- Versandkostenfrei
- Auch auf Rechnung
- Artikel merken
Provisional text
This book offers a comprehensive overview of medullary thyroid carcinoma. The coverage includes, but is not limited to, molecular biology and genetics, pathology, clinical presentation, imaging techniques, surgical treatment, and follow-up. Medullary thyroid carcinoma (MTC) is a rare unique tumor which differs from other thyroid tumors by originating from the neuroendocrine C-cell, secreting the specific tumor marker calcitonin. MTC is associated in about 25% of cases with multiple endocrine neoplasia type 2, an autosomal dominant familial disorder causing tumors within various endocrine glands. The molecular genetics of tumor development is clarified: hereditary as well as sporadic MTC are linked to mutations in the RET proto- oncogene coding for a tyrosine kinase. These RET mutations serve as a genetic marker for hereditary MTC and allow for prophylactic thyroidectomy in gene carriers. The RET-tyrosine kinase is also a new therapeutic target using selective tyrosine kinase inhibitors improving the outcome of advanced metastasized MTC. This book will be an ideal source of up-to-date information for a wide range of practitioners, including endocrinologists, oncologists, internal medicine specialists, geneticists, and nuclear medicine physicians.
This book offers a comprehensive overview of medullary thyroid carcinoma. The coverage includes, but is not limited to, molecular biology and genetics, pathology, clinical presentation, imaging techniques, surgical treatment, and follow-up. Medullary thyroid carcinoma (MTC) is a rare unique tumor which differs from other thyroid tumors by originating from the neuroendocrine C-cell, secreting the specific tumor marker calcitonin. MTC is associated in about 25% of cases with multiple endocrine neoplasia type 2, an autosomal dominant familial disorder causing tumors within various endocrine glands. The molecular genetics of tumor development is clarified: hereditary as well as sporadic MTC are linked to mutations in the RET proto- oncogene coding for a tyrosine kinase. These RET mutations serve as a genetic marker for hereditary MTC and allow for prophylactic thyroidectomy in gene carriers. The RET-tyrosine kinase is also a new therapeutic target using selective tyrosine kinase inhibitors improving the outcome of advanced metastasized MTC. This book will be an ideal source of up-to-date information for a wide range of practitioners, including endocrinologists, oncologists, internal medicine specialists, geneticists, and nuclear medicine physicians.
What is new?.- Thyroid C-Cell Biology and Oncogenic Transformation.- Histopathology of C cells and medullary thyroid carcinoma.- Epidemiology and clinical presentation of Medullary Thyroid Carcinoma.- Medullary thyroid carcinoma: Imaging.- Calcitonin as a Biomarker for Medullary Thyroid Carcinoma.- Hereditary Medullary Thyroid Cancer, Genotype phenotype correlation.- Pheochromocytomas in Multiple Endocrine Neoplasia type 2.- Primary hyperparathyroidism in Multiple Endocrine Neoplasia 2 Syndrome.- Surgical treatment of medullary thyroid carcinoma.- Long term follow up in medullary thyroid carcinoma.- Use of Tyrosine Kinase Inhibitors for Treatment of Medullary Thyroid Carcinoma.
| Erscheint lt. Verlag | 13.5.2025 |
|---|---|
| Reihe/Serie | Recent Results in Cancer Research |
| Zusatzinfo | Approx. 250 p. 80 illus., 25 illus. in color. |
| Verlagsort | Cham |
| Sprache | englisch |
| Maße | 155 x 235 mm |
| Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie |
| Schlagworte | Calcitonin • Multiple Endocrine Neoplasia Type 2 • Pheochromocytoma • Primary Hyperparathyroidism • tyrosinekinase inhibitor |
| ISBN-10 | 3-031-80395-7 / 3031803957 |
| ISBN-13 | 978-3-031-80395-6 / 9783031803956 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
Mehr entdecken
aus dem Bereich
aus dem Bereich
Korrigierter Nachdruck 2020 mit allen Ergänzungen der UICC aus den …
Buch | Softcover (2020)
Wiley-VCH (Verlag)
CHF 59,95
Resilienz innovativ stärken : ein Praxishandbuch
Buch | Softcover (2023)
Kohlhammer (Verlag)
CHF 49,95
